We are today happy to announce that the ESMO Immuno-Oncology 2025 Scientific Committee has selected our abstract “Primers for specific detection of cancer related frameshift mutations in cell free DNA“ for poster (#820) presentation at the ESMO Immuno-Oncology Congress 2025, 10-12 December, London, UK.
CTO of Hubro Bioscience, Henrik Kvalheim Eriksen, says: This is a significant scientific validation of our frameshift detection technology platform and very encouraging for the further development and commercialisation of our first in class in vitro diagnostics (IVDs) that provide simple methods for confirmation of MSI in cancer as well as for surveillance of risk of cancer in individuals of risk populations, and thus, allowing early treatment with potentially improved outcome.